Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem’s t:slim X2 insulin pump.
A hospital room with a patient using a medical device to administer insulin.
The deal settles all pending and prospective litigation about two European patents that Roche filed in December 2023, EP 2 196 231 B1 and EP 1 970 677 B1. Over the next four years, Tandem Diabetes Care, Inc. will pay the remaining $28 million in four equal annual installments after making an initial payment of $8 million.
Both businesses have signed a cross-license agreement as part of the settlement, which will be in place for ten years and grant each other non-exclusive, non-sublicensable, non-royalty-bearing, and irrevocable rights for patents of insulin delivery systems.
This action ends all ongoing legal proceedings under the Unified Patent Court in France and Germany, including infringement, revocation, and non-infringement declarations.
Tandem Diabetes Care, Inc.’s t:slim X2 pump will remain commercially available due to the agreement, which also lowers both companies’ future legal risk.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None.
